Company news

Enliven Therapeutics, Inc. (NASDAQ:ELVN) news

Enliven Therapeutics, Inc. news releases on 6ix. Latest, Oct 6, 2026: Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design…

Enliven Therapeutics, Inc. (NASDAQ:ELVN) news

Press releases & updates

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

/C O R R E C T I O N -- Enliven Therapeutics, Inc./

Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters Option to Purchase Additional Shares

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference

Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results

Imara Announces Stockholder Approval of Merger With Enliven

Enliven Therapeutics and Imara Announce Merger Agreement

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Imara Reports Full Year 2021 Financial Results and Business Highlights

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference